BLRX
BioLineRx Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$2.02
+0.50%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +67.9%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -50.2%
- EBITDA
- —
- EBIT
- +49.2%
- Net income
- +87.2%
- EPS
- +93.7%
- Free cash flow
- +81.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026